Literature DB >> 2878676

Oral xamoterol in patients with sinoatrial disease.

F L Tseu, C A Morley, A F Mackintosh.   

Abstract

Twelve patients with sinoatrial disease were assessed while on oral xamoterol (200 mg twice daily) and placebo by a double blind randomised, crossover trial that lasted four weeks. Nine of the patients had been referred for permanent pacing. Xamoterol produced favourable changes in the number of pauses and the mean heart rate in six patients. Another patient deteriorated on xamoterol. Six patients were started on long term xamoterol. Xamoterol produces short term electrocardiographic improvement in some, but not all, patients with symptomatic sinoatrial disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2878676      PMCID: PMC1236895          DOI: 10.1136/hrt.56.5.469

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  9 in total

1.  Effect of Corwin (ICI 118587) on resting and exercise heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation.

Authors:  A O Molajo; M O Coupe; D H Bennett
Journal:  Br Heart J       Date:  1984-10

2.  Hemodynamic effects of Corwin (ICI 118,587), a new cardioselective beta-adenoceptor partial agonist.

Authors:  J M Detry; P M Decoster; L A Brasseur
Journal:  Eur Heart J       Date:  1983-08       Impact factor: 29.983

3.  Prenalterol in symptomatic sinus node dysfunction.

Authors:  E Feleke; L Rydén; P Smedgård; S Westerling
Journal:  Am Heart J       Date:  1985-01       Impact factor: 4.749

4.  Significance of prolonged electrocardiographic pauses in sinoatrial disease: sick sinus syndrome.

Authors:  M Mazuz; H S Friedman
Journal:  Am J Cardiol       Date:  1983-09-01       Impact factor: 2.778

5.  Mean 24 hour heart rate, minimal heart rate and pauses in healthy subjects 40-79 years of age.

Authors:  P Bjerregaard
Journal:  Eur Heart J       Date:  1983-01       Impact factor: 29.983

6.  The cardiovascular effects of ICI 118,587: A beta 1-adrenoceptor partial agonist.

Authors:  A Nuttall; H M Snow
Journal:  Br J Pharmacol       Date:  1982-10       Impact factor: 8.739

7.  Electrophysiologic effects of hydralazine on sinoatrial function in patients with sick sinus node syndrome.

Authors:  T R Engel; C Leddy; A D Gonzalez; S G Meister; W S Frankl
Journal:  Am J Cardiol       Date:  1978-04       Impact factor: 2.778

8.  Use of amiodarone in bradycardia-tachycardia syndrome.

Authors:  A K Brown; R A Primhak; P Newton
Journal:  Br Heart J       Date:  1978-10

9.  Electrophysiologic effects of theophylline in young patients with recurrent symptomatic bradyarrhythmias.

Authors:  D G Benditt; D W Benson; J Kreitt; A Dunnigan; M R Pritzker; L Crouse; M M Scheinman
Journal:  Am J Cardiol       Date:  1983-12-01       Impact factor: 2.778

  9 in total
  5 in total

Review 1.  Xamoterol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  R Furlong; R N Brogden
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

2.  Preliminary study of the efficacy of xamoterol in bradycardia-tachycardia syndrome.

Authors:  N Mizutani; T Kobayashi; T Watanabe
Journal:  Br J Clin Pharmacol       Date:  1994-09       Impact factor: 4.335

Review 3.  Sinus node disease. Current concepts in diagnosis and therapy.

Authors:  J F Sneddon; A J Camm
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

Review 4.  Drug effects on the sinus node. A clinical perspective.

Authors:  N J Linker; A J Camm
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

5.  Predominant beta-adrenoceptor blocking effect of xamoterol averaged over the day in patients with mild to moderate heart failure: insight into the mechanism of its long-term clinical efficacy.

Authors:  H Ozaki; H Sato; M Hori; T Matsuyama; K Imai; H Yokoyama; A Kitabatake; M Inoue; T Kamada
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.